Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;10(11):14-22.

A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES

Aselin Puthenpurail  1 , Hinal Rathi  1 , Surya M Nauli  2 , Ahmmed Ally  1
Affiliations

A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES

Aselin Puthenpurail et al. World J Pharm Pharm Sci. 2021 Nov.

Abstract

Monoclonal antibodies (mAbs) are increasingly being prescribed to patients and investigated in the field of medicine and research. This class of medication is unique due to its ability to be engineered into targeting a specific receptor. Numerous studies and reviews have reported the efficacy, potency, and clinical usage of mAbs in the treatment of a variety of diseases ranging from autoimmune disorders to malignant cancers. However, very few publications classify and provide a brief synopsis of mAbs that includes their pharmacological profiles. mechanisms of action, uses, and side effects in a concise manner. Therefore, this review aims to classify the current mAbs drugs used in clinical practice according to system diseases by providing a brief summary for each of them. For example, regarding cardiovascular disorders, mAbs such as Abciximab, Bevacizumab, and Digoxin Immune Fab will be reviewed. Denosumab, used to treat musculoskeletal disorders, will be also discussed. In addition, mAbs such as Adalimumab, Eculizumab, Natalizumab used in autoimmune disorders and Alemtuzumab, Trastuzumab, Cetuximab, and Rituximab that are prescribed for tumors will be reviewed. Finally, we shall discuss two mAbs that are IL-6 antagonists, Tocilizumab and Siltuximab, which are in ongoing clinical trials as potential treatments of COVID-19. The mAbs have profound benefits against chronic and malignant conditions, and the overall purpose of this review is to illustrate the basic pharmacological profiles of mAbs that physicians may find useful in establishing their management protocols.

Keywords: Abciximab; Adalimumab; Alemtuzumab; Bevacizumab; Cetuximab; Denosumab; Digoxin Immune FAb; Eculizumab; Monoclonal antibodies; Natalizumab; Rituximab; Siltuximab; Tocilizumab; Transtuzumab; toxicology.

PubMed Disclaimer

Conflict of interest statement

XI. Conflict of Interest The authors declare no conflict of interest.

References

    1. NIH: U.S. National Library of Medicine. Humira - adalimumab kit. DailyMed, viewed 19 August 2020.
    1. Scheinfield N Adalimumab: a review of side effects. Expert opinion on drug safety, 2005; 4(4): 637–641. - PubMed
    1. Benamu E and Montoya JG Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Current opinion in infectious diseases, 2016; 29(4): 319–329. - PubMed
    1. Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF and Durelli L Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opinion on Drug Safety, 2017; 16(8): 963–972. - PubMed
    1. Stoffer K, Bistas KG, Reddy V, Shah S. Abciximab. In: StatPearls, Treasure Island (FL): StatPearls Publishing, 2020. - PubMed

LinkOut - more resources